These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]
5. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348 [TBL] [Abstract][Full Text] [Related]
6. Lenalidomide: an update on evidence from clinical trials. Dimopoulos MA; Terpos E Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633 [TBL] [Abstract][Full Text] [Related]
7. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112 [TBL] [Abstract][Full Text] [Related]
10. Treatment of multiple myeloma in the targeted therapy era. Saad AA; Sharma M; Higa GM Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585 [TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632 [TBL] [Abstract][Full Text] [Related]
15. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib in the front-line treatment of multiple myeloma. Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451 [TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Dimopoulos MA; Christoulas D; Roussou M; Kastritis E; Migkou M; Gavriatopoulou M; Matsouka C; Mparmparoussi D; Psimenou E; Grapsa I; Efstathiou E; Terpos E Eur J Haematol; 2010 Jul; 85(1):1-5. PubMed ID: 20192988 [TBL] [Abstract][Full Text] [Related]
18. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
19. Management of newly diagnosed myeloma. Rajkumar SV; Palumbo A Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592 [TBL] [Abstract][Full Text] [Related]
20. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]